Epithelioid Trophoblastic Tumour: A Case with Genetic Linkage to a Child Born over Seventeen Years Prior, Successfully Treated with Surgery and Pembrolizumab
DI FIORE, Riccardo
O'Leary, John J.
Beirne, James J.
O'Toole, Sharon A.
GroupCenter for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine (Temple University)
Permanent link to this recordhttp://hdl.handle.net/20.500.12613/8114
MetadataShow full item record
AbstractEpithelioid trophoblastic tumours are rare neoplasms showing differentiation towards the chorion leave-type intermediate cytotrophoblast, with only a handful of cases being reported in the literature. These tumours are slow-growing and are typically confined to the uterus for extended periods of time. While the pathogenesis is unclear, they are thought to arise from a remnant intermediate trophoblast originating from prior normal pregnancies or, less frequently, gestational trophoblastic tumours. A protracted time period between the gestational event and tumour development is typical. This case describes a 49-year-old previously healthy female who presented with a completely asymptomatic uterine mass, discovered incidentally during a routine gynaecological assessment. The pathological analysis of the hysterectomy specimen confirmed an epithelioid trophoblastic tumour, involving the uterus and cervix. This is a rare gynaecological tumour. A comparative short tandem repeat analysis revealed genetic similarities to a previous healthy gestation seventeen years prior. She was successful treated with adjuvant pembrolizumab, with no evidence of disease recurrence to date.
CitationPisani D, Calleja-Agius J, Di Fiore R, O’Leary JJ, Beirne JP, O’Toole SA, Felix A, Said-Huntingford I. Epithelioid Trophoblastic Tumour: A Case with Genetic Linkage to a Child Born over Seventeen Years Prior, Successfully Treated with Surgery and Pembrolizumab. Current Oncology. 2021; 28(6):5346-5355. https://doi.org/10.3390/curroncol28060446
Citation to related workMDPI
Has partCurrent Oncology, Vol. 28
ADA complianceFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact email@example.com